Mylan dumps its 5.64% Biocon stake in ₹4,000 cr open-market sale
Long-term biosimilars partner sells entire 9.19 crore shares in a single day. Exit removes a strategic investor and creates a supply overhang.
— 1 earlier story on Biocon Ltd. →What's new
- Mylan sold its entire 5.64% stake in Biocon (9.19 crore shares) on July 14.
- The sale was conducted on the open market in a single transaction.
- Mylan now holds zero equity shares in Biocon.
Why this matters
Mylan was a long-standing strategic partner in biosimilars. Its full exit signals a potential change in the partnership dynamic and adds a ₹4,000 crore supply overhang for a stock already trading at a trailing P/E of 174.9 and a ROE of just 4.7%.
What we're watching
- Any official statement from Biocon or Mylan on the future of their biosimilars alliance.
- Stock price reaction to the block sale and if any institutional buyer steps in.
- Whether Mylan's exit triggers further selling by other long-term holders.
The full read
Mylan walked away. On July 14, the American pharma company dumped its entire 5.64% stake in Biocon — 9.19 crore shares worth roughly ₹4,000 crore in a single open-market transaction. No explanation. The sale ends a long-standing biosimilars partnership and removes a strategic investor from the register. For Biocon, the supply overhang is material: the stock carries a trailing P/E of 174.9, a ROE of just 4.7%, and a debt-to-equity ratio of 0.82. The latest quarter (Mar 2026) showed sales of ₹4,517 crore but net profit of only ₹199 crore, with trailing PAT down 56.8%. Mylan gave no reason. The open question is what happens to the biosimilars alliance now.
Questions answered
- How much did Mylan sell and at what price?
- Mylan sold 9.19 crore shares (5.64% stake) on July 14. At prevailing prices the sale was worth approximately ₹4,000 crore.
- Why did Mylan exit Biocon?
- The filing does not give a reason. Mylan disclosed the sale under SEBI Takeover Regulations but offered no explanation for the complete exit.
- What is the history between Mylan and Biocon?
- Mylan and Biocon have a long-standing partnership in biosimilars. Mylan held the 5.64% stake as a strategic investor, part of a broader alliance to develop and commercialise biosimilar products.
- How does this affect Biocon's fundamentals?
- The sale itself does not change Biocon's operations, but it removes a strategic partner and creates a large share supply overhang. Biocon's latest quarter (Mar 2026) showed sales of ₹4,517 crore and net profit of ₹199 crore, with trailing PAT down 56.8%.
Biocon Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on BIOCON →- 15 Jul 2026 · 1:30 PM IST Mylan dumps its 5.64% Biocon stake in ₹4,000 cr open-market sale
- 21d ago Biocon scores MYR 225 mn insulin supply deal in Malaysia